Northern Lights

BerGenBio (Sell, TP: NOK0.05) - Too little before it’s too late

Following the recent rights issue and detrimental terms for the stock, we remain concerned about the company’s ability to produce substantial share-price catalysts during its financial runway (we estimate until 2024e). We struggle to see the current phase Ib/IIa study producing results considered attractive enough for investors ahead of the next needed capital raise. We reiterate our SELL and have cut our target price to NOK0.05 (0.11).

Genmab (Buy, TP: DKK2630.00) - Epinkly off to a good start in 2024

Q1 sales beat our forecast and consensus due to higher product-related royalties and solid Epkinly sales, while the operating profit margin was softer than expected owing to higher opex. Genmab reiterated the 2024 guidance for sales of DKK18.7bn–20.5bn, opex of DKK12.4bn–13.4bn, and operating profit of DKK4.6bn–7.1bn. We expect a strong pipeline of news flow in 2024. We reiterate our BUY and DKK2,630 target price.

The weekly navigator

From the past week, we highlight: 1) we raised our target price on Latour to SEK285 (280), but reiterated our HOLD; 2) Kinnevik-owned Lunar raised SEK282m of new capital; and 3) we will host an investor lunch with Latour’s CEO Johan Hjertonsson at our Stockholm office next week.

Aker BP (Buy, TP: NOK290.00) - Capex concerns looming

While investor concerns appear tilted towards a near-term production decline, we are increasingly concerned that consensus FCF will face meaningful negative revisions, as capex assumptions beyond 2026 look far too low. For 2027–2030, our FCF estimates are ~40% below consensus. We reiterate our BUY, but have cut our target price to NOK290 (325) on a lower fair P/NAV.